股市必读：英科医疗（300677）10月21日主力资金净流出1.05亿元

Core Viewpoint - The company, Yingke Medical, is actively engaging in investment and stock incentive plans, indicating a strategic focus on growth and shareholder value enhancement through various financial maneuvers [1][2][4]. Trading Information Summary - On October 21, 2025, Yingke Medical's stock closed at 41.66 yuan, down 0.83%, with a turnover rate of 4.35%, a trading volume of 202,400 lots, and a transaction amount of 847 million yuan [1]. - On the same day, the net outflow of main funds was 105 million yuan, while speculative funds and retail investors saw net inflows of approximately 58.91 million yuan and 45.66 million yuan, respectively [1][4]. Company Announcement Summary - The fourth board meeting of Yingke Medical on October 20, 2025, approved several resolutions, including a plan for its wholly-owned subsidiary to invest 70 million USD in Warburg Pincus Global Growth 15, L.P., which targets a fundraising goal of at least 17 billion USD across various sectors [1]. - The company agreed to lift the restrictions on the third phase of the 2022 restricted stock incentive plan, involving 540 participants and a total of 1,052,520 shares, which accounts for 0.1607% of the current total share capital [2]. - Due to changes in equity distribution and other factors, the company plans to adjust its registered capital from 641.700369 million yuan to 654.383263 million yuan, with corresponding amendments to its articles of association [2][4]. - The company intends to repurchase and cancel a total of 410,480 shares from the restricted stock incentive plans of 2022 and 2025, with adjusted repurchase prices set at 10.91 yuan and 11.25 yuan per share, respectively [2][4]. Upcoming Events Summary - Yingke Medical will hold its sixth extraordinary general meeting on November 5, 2025, to discuss the adjustment of the restricted stock repurchase price and the cancellation of certain restricted stocks, requiring a two-thirds majority vote from attending shareholders [3].